Displaying 126–150 of 11035 results for

Sort By Relevance Sort By Date
1... 4 5 6 7 8 ...442

Synthorx founder mysteriously leaves Scripps Research

(News)

A lead scientist at La Jolla’s Scripps Research has left the biomedical institute

Funny Pharm: You Write the Caption & Win: August 2019

funny pharma cartoon caption contest

What are the Pharma Innovation Awards?

(Article)

The annual Pharma Innovation Awards are our brand's way of acknowledging the investment pharmaceutical equipment vendors put into developing and improving their products.

After several acquisitions, Cambrex is now on track to be bought

(News)

One of the industry’s leading small-molecule CDMOs is being acquired for $2.4 billion.

Teva’s CFO resigns in the midst of ongoing financial woes

(News)

Teva Pharmaceuticals announced this week that its chief financial officer is stepping down.

Novo Nordisk buys Purdue Pharma plant

(News)

In an attempt to streamline its supply chain of diabetes drugs in the U.S., Novo Nordisk has scooped up a plant from Purdue Pharma.

FDA says Novartis gene therapy drug application contains manipulated data

(News)

On May 24, the FDA approved Zolgensma, a gene therapy product intended to treat children less than two years of age with spinal muscular atrophy but was informed recently by the product’s manufacturer about a data manipulation issue that impacts the accuracy of certain data.

GSK drops Ebola vaccine development

(News)

The vaccine candidates will be transferred to the Sabin Vaccine Institute in Washington

Roche’s Tecentriq clears new hurdle in bladder cancer

(News)

Roche’s Tecentriq is showing new promise as an early treatment for bladder cancer.

States probe Eli Lilly over insulin prices

(News)

Eli Lilly has been hit with a subpoena from the New York Attorney General’s Office over the pricing and sales of its insulin treatments.

Union says Takeda employees treated unfairly during merger

(News)

Takeda Pharma's Korean labor union said Takeda employees faced unfair changes in their jobs and roles during the Takeda Korea and Shire Korea merger.

Fujifilm drops $890M on Danish biologics campus

(News)

Fujifilm has acquired a large-scale biologics site near Copenhagen, Denmark.

Oklahoma guns for $17B settlement in J&J opioid litigation

(News)

Oklahoma’s attorney general has made a final attempt to hold Johnson & Johnson’s feet to the fire for its role in the opioid epidemic.

Pharma in review: trending stories 8/2/19

(News)

pharma manufacturing news in review

Research report: Data — the land of lost opportunity

(Whitepaper)

Without the right data management systems in place, data is nothing more than spreadsheets of wasted opportunity for improvement.

What’s behind all the M&A deals in pharma?

(Article)

As far as M&A deals go, 2019 has started off with a boom.

Mylan looks to settle EpiPen probe for $30M

(News)

Mylan has reached a tentative agreement to resolve an investigation that it underpaid the government for EpiPens.

Trump forms plan to allow imported meds from Canada

(News)

In his latest attempt to lower the costs of prescription drugs, President Trump has proposed a plan to allow imports from Canada.

FTC probing J&J over arthritis drug Remicade

(News)

The organization issued a civil investigative demand to the drugmaker to see if its biosimilar defense strategy violates federal antitrust laws.

Celgene resolves cancer drug antitrust case with Mylan

(News)

The drugmaker will pay Mylan $62 million for improperly stifling competition for its cancer drugs.

New painkiller that seemed destined for greatness may only get limited FDA nod

(News)

One of the buzziest new painkillers in trials for the last few years has been Pfizer and Ely Lilly’s tanezumab, a nerve growth factor drug.

Novartis CEO says he won't sell Sandoz unit

(News)

Novartis CEO Vas Narasimhan pledged in a published interview that the Swiss drugmaker will not sell its generics unit amid a revamp that has prompted rumors about offloading Sandoz.

Potential Novartis blockbuster misses the mark in new study

(News)

Novartis’ Entresto already has the potential to hit $3 billion in sales for its current heart failure indication, and with another indication in mind, the company hoped sales could hit $5 billion.

Pfizer to combine off-patent drug business with Mylan

(News)

Pfizer has agreed to merge its off-patent drugs business with generic drugmaker Mylan.

Sort By Relevance Sort By Date
1... 4 5 6 7 8 ...442